J. Goldman & Co’s Applied Therapeutics APLT Stock Holding History

J. Goldman & Co’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-146,392	Closed	-$693K	–	439
2024 Q1	$995K	Buy	+146,392	New	+$657K	0.03%	271

Other funds holding APLT

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

J. Goldman & Co's APLT Position: Q2 2024 in Review

J. Goldman & Co sold out of Applied Therapeutics (APLT) in Q2 2024, closing a stake of 146,392 shares — an estimated $693K sold.

J. Goldman & Co first reported a position in APLT in Q1 2024 and held it in 1 quarter. The position peaked at $995K in Q1 2024. 94 funds tracked by Wall St. Rank hold APLT as of Q2 2024.

J. Goldman & Co reported no remaining Applied Therapeutics position as of Q2 2024 after selling out during the quarter.
J. Goldman & Co sold 146,392 Applied Therapeutics shares in Q2 2024, an estimated $693K.
J. Goldman & Co first reported a position in Applied Therapeutics in Q1 2024 and held it in 1 quarter.
J. Goldman & Co's Applied Therapeutics position peaked at $995K in Q1 2024.
94 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2024.

Based on J. Goldman & Co's 13F filing for Q2 2024, filed 14 Aug 2024.